Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -2024202320222021202020192018201720162015 1 September 2022 Biocartis Announces Entry into Comprehensive Recapitalization Arrangements to Strengthen Cash Position and Support Growth Inside information Regulated information 17 August 2021 Second Update on Fire Incident at Biocartis Warehouse Inside information Regulated information 22 April 2021 Biocartis and SkylineDx Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™ Inside information Regulated information 7 December 2020 Biocartis Announces the Conversion of EUR 15 million of its EUR 150 million 4% Convertible Bonds due 2024 Inside information Regulated information 29 October 2020 Biocartis and Exact Sciences Agree to End Collaboration Due to Changed Market Circumstances Inside information Regulated information 29 October 2020 Update on the Partnership with Exact Sciences Inside information Regulated information 22 April 2020 Biocartis Q1 2020 business update Inside information Regulated information 27 January 2020 Biocartis announces resignation CFO Inside information Regulated information 7 January 2019 Biocartis Announces Achieving its 2018 Key Business Objectives Inside information Regulated information 3 September 2018 Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla Platform in China Inside information Regulated information Pagination First page « First Previous page ‹‹ Page 1 Current page 2 Page 3 Next page ›› Last page Last »